Linear oligonucleotide and use in the detection of analytes of interest
Patent Information
- Application Number
- EP2022844109
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-27
- Filing Date
- 2022-12-22
- Publication Date
- 2024-11-06
AI Technical Summary
Current methods for detecting analytes in liquid samples, such as ELISA and PCR-based techniques, face limitations in sensitivity and complexity, especially when detecting analytes at low concentrations, and require multiple antibodies or enzymes, making them costly and time-consuming.
A linear oligonucleotide with a modified structure, comprising specific portions and entities for analyte recognition, is used for LAMP amplification with only two primers, allowing for isothermal detection and quantification without the need for complex primer designs or additional enzymes.
This approach enables efficient, sensitive, and cost-effective detection and quantification of analytes, simplifying the process by reducing the complexity of primer design and synthesis, while maintaining high sensitivity and specificity.
Smart Images

Figure 1.1
Abstract
Description
[0001] LINEAR OLIGONUCLEOTIDE AND USE IN THE DETECTION OF ANALYTES OF INTEREST
[0002] DESCRIPTION
[0003] TECHNICAL FIELD
[0004] The present invention relates to the field of tools and methods for detecting molecules of interest.
[0005] More particularly, the present invention provides a particular linear oligonucleotide structure, useful in particular for detecting and possibly quantifying at least one analyte of interest in a liquid sample using two-primer LAMP (for "Loop-mediated isothermal AMPlification") amplification. The present invention also relates to such a method of detection and possible quantification.
[0006] STATE OF THE PRIOR ART
[0007] Numerous works and studies in fields including academic research; clinical and diagnostic research and analyses, with tests carried out on blood samples or cell or tissue biopsies; environmental monitoring; civil surveillance; food safety and in particular quality control; criminal trace analyses... involve the detection of biomarkers, molecules of interest or contaminants in a sample and in particular in a liquid sample.
[0008] Several techniques have been developed for this purpose.
[0009] A first immunoenzymatic detection technique called ELISA (for "Enzyme-Linked ImmunoSorbent Assay") was developed in the early 1970s. Among the different implementations used in this technique, a sandwich between two specific antibodies and the target can be made. The first antibody is used to capture the target, for example, at the bottom of a well, while the second antibody is used for enzymatic amplification, directly or via a secondary antibody coupled to an enzyme such as HRP (for "Horse Radish Peroxidase"). The ELISA method uses an antibody and allows quantification of the target using a calibration range carried out beforehand or simultaneously. This method is still widely used today and many variations exist.Indeed, an aptamer, which is an oligonucleotide sequence specifically selected for its interaction with an analyte or any other oligonucleotide sequence with a specific affinity towards an analyte, can be used instead of an antibody and applied as a probe in an ELISA method. Aptamers are a good alternative to antibodies because, having an affinity similar to that of antibodies, they can detect small molecules and because they are very specific for a target, much easier to produce and handle, more stable and less expensive.
[0010] However, when the target to be detected is present in very low concentrations in the sample, the ELISA technique with antibodies or aptamers proves ineffective and does not allow low detection limits to be achieved. To solve this problem, amplification of a DNA probe is generally necessary.
[0011] Therefore, other detection methods have been developed using polymerase chain reaction (PCR). Specific examples of such methods include immuno-PCR and aptamer-PCR.
[0012] In immuno-PCR, the enzymatic amplification of the ELISA technique is replaced by DNA amplification. The second antibody is then coupled to a DNA sequence which is exponentially amplified by PCR. This method is very specific and quantitative but it still requires the presence of two antibodies specific to the target and in particular the development of an antibody coupled to DNA, which makes this method complicated and expensive.
[0013] Aptamero-PCR, on the other hand, allows the secondary antibody to be replaced by an oligonucleotide containing an aptamer sequence specific to the target to be detected. Detection is achieved by direct amplification of this probe by PCR. This method achieves a detection limit of a few picomolars. However, both immuno-PCR and aptamero-PCR have the disadvantages of PCR, namely the need for relatively long temperature cycles involving different temperatures.
[0014] Finally, another amplification method has been developed to replace PCR in the amplification of double strands of DNA. This method, called LAMP and patented [1], has the major advantage of being isothermal, the amplification being carried out at a constant temperature typically between 60°C and 65°C, and allowing rapid detection.
[0015] Thus, a protein detection method with LAMP amplification was described by Pourhassan-Moghaddam et al, 2013 [2]. It uses, on the one hand, an antibody or an aptamer attached to a surface to capture the target and, on the other hand, an oligonucleotide containing an aptamer sequence that recognizes the target. This oligonucleotide is then amplified by the classic LAMP method with four primers.
[0016] However, the complex design of the four primers essential to the LAMP amplification method makes this process complex and relatively long to implement, despite the development of numerous LAMP primer design software programs such as, for example, LAMP designer (OPtigene) or primer Explorer.
[0017] Finally, a method for detecting microRNAs (miRNAs) using a LAMP method with two primers has been developed [3, 4]. This method has the advantage of being quantitative. However, it can only detect RNA from which a complementary DNA fragment (cDNA) is formed using a reverse transcription reaction. Two hairpin DNA probes designated H1 and H2 in Du et al, 2016 [4] are designed, with the H1 probe having at its 3' end an extension complementary to half of the cDNA fragment and the H2 probe having at its 5' end an extension complementary to the other half of the cDNA fragment. In the presence of the cDNA fragment, the H1 and H2 probes hybridize to it and, if no mismatch exists between the extensions of the H1 and H2 probes and the cDNA fragment, a covalent bond between the two DNA probes H1 and H2 can be formed using a high-fidelity ligase such as Taq DNA ligase.It is therefore clear that this method of miRNA detection is not generic since it requires the preparation of two probes specific to each miRNA to be detected. Furthermore, this method involves several steps before the implementation of the LAMP technique with a reverse transcription step and a ligation step, the latter of which can be complex with a possibly low yield and the need to use an additional enzyme. Despite this, in their publication Du et al, 2016 [4], the authors insist on the fact that this step is essential, in particular for better discrimination of mutations in miRNAs (sentence bridging the columns on page 12722).
[0018] The inventors have already developed an innovative method for performing LAMP amplification with only two primers [5, 6]. This method makes it possible to detect analytes of interest of various types in a sample and does not have the disadvantages of the prior art methods. It uses a sequence in the form of a double stem-loop oligonucleotide, also known as a "dumbbell", serving as a template for LAMP amplification and eliminating the first steps of this amplification. It makes it possible to combine the recognition of analytes by oligonucleotide strands and LAMP amplification with two primers, and provides high-sensitivity detection. Indeed, the double stem-loop oligonucleotide used incorporates, within its structure [5] or at one of its ends [6], an entity for recognizing the analyte of interest.
[0019] The inventors therefore set themselves the goal of proposing a useful tool in a method for detecting molecules of interest of various natures in a sample, said method not having the drawbacks of the methods of the state of the art and making it possible to further improve the oligonucleotide with a double stem-loop structure described in [5, 6], DISCLOSURE OF THE INVENTION
[0020] The present invention makes it possible to solve the technical problems and drawbacks previously listed. Indeed, the inventors have proposed a new oligonucleotide tool particularly useful in a method for detecting and possibly quantifying an analyte, which makes it possible to take advantage of the benefits of two-primer LAMP amplification, namely an isothermal, quantifiable method requiring only two primers.
[0021] The oligonucleotide tool that is the subject of the present invention is a linear oligonucleotide that is clearly distinguished from the oligonucleotides with a double stem-loop structure described in [5, 6]. Indeed, the sequence of the oligonucleotide according to the invention implemented is modified to become shorter, ideally less than 100 bases. This makes it possible in particular to envisage a simpler, more efficient chemical synthesis with a high yield and easier and more economical purification.
[0022] More particularly, the portions F1 and B1 as defined in the oligonucleotides with a double stem-loop structure described in [5, 6] have been deleted in the oligonucleotide according to the invention, thus preventing any hybridization and therefore the formation of stem-loop structures. This oligonucleotide comprising the portions F2, F1, F1c and B2c can then be modified by adding an entity specific to the analyte to be detected or usable for this detection at various locations in the sequence, in particular in 5' or 3' but also between F2 and F1, between F1 and F1c or between F1c and B2c.
[0023] In other words, the linear oligonucleotide according to the invention does not comprise a portion (Fie) whose nucleotide sequence is complementary to the nucleotide sequence of the portion Fl, nor a portion (Bl) whose nucleotide sequence is complementary to the nucleotide sequence of the portion Blc, said portions Fl and Blc being present in this oligonucleotide. The melting temperatures (Tm) of Fl-Flc and Bl-Blc are as defined later herein.
[0024] Thus, it is easy to prepare the oligonucleotide according to the invention from the sequence of all FIP (for "Forward Inner Primer") and BIP (for "Backward Inner Primer") primers described in the prior art. Indeed, the oligonucleotide which is the subject of the invention comprises an F2 portion also present in the FIP primer, an Fl portion whose nucleotide sequence is complementary to the nucleotide sequence of the Fie portion present in the FIP primer, a Blc portion also present in the BIP primer and a B2c portion whose nucleotide sequence is complementary to the nucleotide sequence of the B2 portion present in the BIP primer.
[0025] For the purposes of the present invention, two nucleotide sequences are complementary to each other when a sufficient number of nucleotides of the first nucleotide sequence can bond, by means of hydrogen bonds, with the corresponding nucleotides of the second nucleotide sequence such that pairing between the two nucleotide sequences can occur. "Complementarity," as used herein, refers to the pairing capacity between nucleotides of a first nucleotide sequence and a second nucleotide sequence. Non-complementary nucleotides between two nucleotide sequences can be tolerated provided that the two nucleotide sequences remain capable of specifically hybridizing to each other.In addition, a first nucleotide sequence may hybridize to one or more segments of a second nucleotide sequence such that intervening or adjacent segments are not involved in the hybridization. In some embodiments of the invention, a first nucleotide sequence or a specific portion thereof is at least 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% complementary to a second nucleotide sequence or a specified portion thereof.
[0026] Surprisingly and contrary to what a person skilled in the art might think, bringing the linear oligonucleotide according to the invention into contact with the two primers FIP of sequence 5'-Flc-F2-3' and BIP of sequence 5'-Blc-B2-3', conventionally used in two-primer LAMP amplifications, does indeed give rise to exponential amplification, as described in the experimental section below.
[0027] The linear oligonucleotide, object of the present invention, corresponds to the following formula (I):
[0028] Sa-F2-Sb-Fl-lnt-Blc-Sc-B2c-Sd (I) in which
[0029] Sa represents the 5' end of the F2 portion or a structure comprising at least one entity E capable of binding, directly or indirectly, to an analyte of interest, the F2 portion comprises from 8 to 30 nucleotides,
[0030] Sb separating the F2 portion and the Fl portion is either a covalent bond or a portion comprising at least one entity E capable of binding, directly or indirectly, to an analyte of interest, the Fl portion comprises from 10 to 35 nucleotides,
[0031] Int separating the Fl portion and the Blc portion is chosen from the group consisting of a covalent bond, a portion comprising at least one nucleotide and a portion comprising at least one entity E capable of binding, directly or indirectly, to an analyte of interest, the Blc portion comprises from 10 to 35 nucleotides,
[0032] Sc separating the Blc portion and the B2c portion is either a covalent bond or a portion comprising at least one entity E capable of binding, directly or indirectly, to an analyte of interest, the B2c portion comprises from 8 to 35 nucleotides, and
[0033] Sd represents the 3' end of portion B2c or a structure comprising at least one entity E capable of binding, directly or indirectly, to an analyte of interest, provided that at least one of Sa, Sb, Int, Sc and Sd comprises a structure or portion comprising at least one entity E capable of binding, directly or indirectly, to an analyte of interest.
[0034] The linear oligonucleotide according to the invention may comprise two, three, four or five structures or portions comprising at least one entity E capable of binding, directly or indirectly, to an analyte of interest. Advantageously, the linear oligonucleotide according to the invention comprises a single structure or portion comprising at least one entity E capable of binding, directly or indirectly, to an analyte of interest.
[0035] In other words, the linear oligonucleotide according to the invention corresponds to any one of the following formulas (II), (III), (IV), (V) and (VI):
[0036] Sa'-F2-Fl-lnt'-Blc-B2c (II)
[0037] F2-Sb'-Fl-lnt'-Blc-B2c (III)
[0038] F2-Fl-lnt"-Blc-B2c (IV)
[0039] F2-Fl-lnt'-Blc-Sc'-B2c (V) and
[0040] F2-Fl-lnt'-Blc-B2c-Sd' (VI) in which the portions F2, Fl, Blc and B2c are as previously defined,
[0041] Int' separating the Fl portion and the Blc portion is either a covalent bond or a portion comprising at least one nucleotide, and
[0042] Sa', Sb', Int'', Sc' and Sd' represent a structure or portion comprising at least one entity E capable of binding, directly or indirectly, to an analyte of interest.
[0043] In a more particular embodiment, the linear oligonucleotide according to the invention corresponds to the following formula (II) or (VI):
[0044] Sa'-F2-Fl-lnt'-Blc-B2c (II)
[0045] F2-Fl-lnt'-Blc-B2c-Sd' (VI) in which the portions F2, Fl, Blc and B2c are as previously defined,
[0046] Int' separating the Fl portion and the Blc portion is either a covalent bond or a portion comprising at least one nucleotide, and
[0047] Sa' and Sd' represent a structure comprising at least one entity E capable of binding, directly or indirectly, to an analyte of interest. In the linear oligonucleotide according to the invention, the portion F2 may comprise from 10 to 27 nucleotides and, as a particular example, 21 or 24 nucleotides.
[0048] In the linear oligonucleotide according to the invention, the Fl portion may comprise from 15 to 25 nucleotides and, as particular examples, 19, 20, 21 or 22 nucleotides. Furthermore, the Fl portion has a nucleotide sequence complementary to the nucleotide sequence of the Fie portion present in the FIP primer used during the two-primer LAMP amplification. The melting temperature (Tm) of Fl-Flc is typically higher than the temperature used during the amplification (typically between 55°C and 65°C). The Tm of Fl-Flc is higher than the temperature used during the amplification advantageously by at least 5°C, in particular by at least 7°C and, in particular, by at least 10°C. Those skilled in the art will be able to find additional information regarding these portions in [1],
[0049] In the linear oligonucleotide according to the invention, the Blc portion may comprise from 17 to 27 nucleotides and, as particular examples, 18 or 25 nucleotides. Furthermore, the Blc portion has a nucleotide sequence complementary to the nucleotide sequence of the B1 portion present in the BIP primer used during the two-primer LAMP amplification. The melting temperature (Tm) of Bl-Blc is in particular higher than the temperature used during the amplification. The Tm of Bl-Blc is higher than the temperature used during the amplification advantageously by at least 5°C, in particular by at least 7°C and, in particular, by at least 10°C. Those skilled in the art will be able to find additional information regarding these portions in [1],
[0050] In the linear oligonucleotide according to the invention, the B2c portion may comprise from 15 to 30 nucleotides and, as particular examples, 18 or 22 nucleotides.
[0051] In the linear oligonucleotide according to the present invention, when Int or Int' represents a portion comprising at least one nucleotide, the latter may comprise up to 3 nucleotides, 10 nucleotides, 30 nucleotides, 50 nucleotides and even 70 nucleotides and does not comprise any structure comprising at least one entity E capable of binding, directly or indirectly, to an analyte of interest. Advantageously, the linear oligonucleotide according to the invention comprises less than 180 nucleotides, in particular less than 160 nucleotides, in particular less than 150 nucleotides, more particularly less than 140 nucleotides and most particularly less than 130 nucleotides.
[0052] In certain embodiments, the linear oligonucleotide according to the invention may comprise less than 130 nucleotides, in particular less than 120 nucleotides, in particular less than 110 nucleotides, more particularly less than 100 nucleotides and most particularly less than 90 nucleotides, in particular when the structure(s) or portion(s) comprising at least one entity E capable of binding, directly or indirectly, to an analyte of interest does not have any nucleotide.
[0053] With such a size, the chemical synthesis of this oligonucleotide is facilitated and the cost of this synthesis and, consequently, the cost of the method according to the invention are lower.
[0054] The structure or portion Sa, Sb, Int, Sc, Sd, Sa', Sb', Int'', Sc' or Sd' in the oligonucleotide according to the invention may comprise only one entity E as previously defined. In this first variant, the structure or portion Sa, Sb, Int, Sc, Sd, Sa', Sb', Int'', Sc' or Sd' consists of one entity E. In other words, this entity E is linked:
[0055] - via a covalent bond, at the 5' end of the F2 portion, or
[0056] - via a covalent bond, at the 3' end of the B2c portion, or
[0057] - either via a first covalent bond at the 3' end of F2 and via a second covalent bond at the 5' end of Fl, or
[0058] - either via a first covalent bond at the 3' end of Fl and via a second covalent bond at the 5' end of Blc, or
[0059] - either via a first covalent bond at the 3' end of Blc and via a second covalent bond at the 5' end of B2c.
[0060] In a second variant, the structure or portion Sa, Sb, Int, Sc, Sd, Sa', Sb', Int'', Sc' or Sd' in the oligonucleotide according to the invention may comprise, in addition to an entity E as previously defined, at least one other element making it possible to link the entity E to the 5' end of the portion F2, to the 3' end of the portion F2, to the 3' end of the portion F1, to the 5' end of the portion F1, to the 5' end of the portion Blc, to the 3' end of the portion Blc, to the 5' end of the portion B2c and / or to the 3' end of the portion B2c. This additional element is known as a "linker arm" and serves to improve the accessibility of the entity E.Those skilled in the art know different examples of such elements that can be used in the context of the present invention [5, 6]. As examples, mention may be made of a nucleotide molecule as previously defined and in particular a sequence comprising several thymine bases and in particular 10 thymine bases, a polymer such as, for example, a polyethylene glycol (PEG) or a streptavidin-biotin molecular structure. These last two examples (polymer and molecular structure) are in particular more suitable for the Sa, Sd, Sa' and Sd' structures in the oligonucleotide according to the invention. The bonds used in this variant are non-covalent and low-energy bonds such as hydrogen bonds or Van der Waals bonds and / or high-energy bonds of the covalent bond type.
[0061] In a third variant, the structure or portion Sa, Sb, Int, Sc, Sd, Sa', Sb', Int'', Sc' or Sd' in the oligonucleotide according to the invention may comprise several entities E as previously defined, identical or different. In this variant, two successive entities E may optionally be separated by a linker arm. Similarly, these entities may optionally be linked to the 5' or 3' end of the adjacent portion via a linker arm. Finally, when the structure or portion Sa, Sb, Int, Sc, Sd, Sa', Sb', Int'', Sc' or Sd' has several linker arms, these may be identical or different.
[0062] In a first embodiment, the entity(ies) E present at the structure or portion Sa, Sb, Int, Sc, Sd, Sa', Sb', Int'', Sc' or Sd' in the oligonucleotide according to the invention are capable of binding directly to at least one analyte of interest. An entity E according to this embodiment may also be designated, herein, by the expression "recognition entity".
[0063] This entity may be any molecule capable of forming with the analyte to be detected a pair of elements forming a bond, also referred to as a "binding pair". The entity E and the analyte correspond to the two partners of this binding pair. The bonds implemented in the analyte-entity bond are advantageously non-covalent and low-energy bonds such as hydrogen bonds or Van der Waals bonds and / or high-energy bonds of the covalent bond type. Non-covalent and low-energy bonds will be implemented in particular when the entity E is found in any of the aforementioned portions or structures and, in particular, in the portion Sb, Sb', Int, Int'', Sc or Sc'. High-energy bonds may be implemented in the structures Sa, Sa', Sd and Sd'. Indeed, in these structures, high energy bonds will not affect LAMP amplification.
[0064] The recognition entity(ies) used are therefore dependent on the analyte(s) to be detected. Depending on the latter, the person skilled in the art will be able, without inventive effort, to choose the most suitable entity(ies). A recognition entity may be chosen, for example, from the group consisting of a carbohydrate; a peptide such as an antimicrobial peptide or a MIP for “MHC class I peptide” i.e. a peptide associated with MHC-1 (for “Major Histocompatibility Complex-1”); an antigen; an epitope; a protein; a glycoprotein; an enzyme; an enzyme substrate; a membrane or nuclear receptor; an agonist or antagonist of a membrane or nuclear receptor; a toxin; a polyclonal or monoclonal antibody; an antibody fragment such as a Fab, F(ab')2, Fv fragment or a hypervariable domain (or CDR for “Complementarity Determining Region”); a nucleotide molecule; and an aptamer.
[0065] Note that an entity forming a pair of bonds with an analyte of interest is advantageously presented in the form of a nucleotide sequence, when this entity is included in the portion Sb, Sb', Int, Int'', Sc or Sc'.
[0066] The term "nucleotide molecule" as used herein is equivalent to the following terms and expressions: "nucleic acid", "polynucleotide", "nucleotide sequence", "polynucleotide sequence" and "oligonucleotide sequence". By "nucleotide molecule", is meant, in the context of the present invention, a chromosome; a gene; a regulatory polynucleotide; a DNA, single-stranded or double-stranded, genomic, chromosomal, chloroplast, plasmid, mitochondrial, recombinant or complementary; a total RNA; a messenger RNA; a ribosomal RNA (or ribozyme); a transfer RNA; a micro-RNA; a small interfering RNA; a sequence acting as an aptamer; a peptide nucleic acid; a locked nucleic acid (or LNA for "Locked Nucleic Acid"); a morpholino; a portion or fragment thereof.
[0067] In a second embodiment, particularly illustrated in the experimental part below, the entity(ies) E present at the structure or portion Sa, Sb, Int, Sc, Sd, Sa', Sb', Int”, Sc' or Sd' are capable of binding indirectly to one or more analytes of interest. This second embodiment applies in particular to the case where the entity(ies) E are present at the structure Sa, Sd, Sa' or Sd'. In other words, this or these entity(ies) E are independent of the analyte(s) of interest to be detected and this detection requires the use of a binding intermediate capable of binding, on the one hand, to the oligonucleotide according to this second embodiment of the invention and, on the other hand, to the analyte(s) of interest.This binding partner corresponds to a molecule comprising a first portion PI capable of binding to an entity E present in the structure or portion Sa, Sb, Int, Sc, Sd, Sa', Sb', Int”, Sc' or Sd' of the oligonucleotide and in particular in the structure Sa, Sd, Sa' or Sd' and a second portion P2 capable of binding to at least one analyte of interest. The portion P2 of this molecule corresponds to a recognition entity as defined above or comprises several recognition entities as defined above, identical or different. Thus, everything described above for the recognition entity or entities applies mutatis mutandis to the portion P2. In this binding partner, the portion PI and the portion P2 are coupled to each other by means of a covalent bond. Alternatively, the portion PI and the portion P2 may be coupled to each other by means of a linker arm as defined above.
[0068] An entity E of this second embodiment may be any molecule capable of forming a binding pair with the PI portion of the binding partner, the entity E and the PI portion corresponding to the two partners of this binding pair. The bonds implemented in the entity-PI portion bond are non-covalent and low-energy bonds such as hydrogen bonds or Van der Waals bonds. The present invention relates to a non-covalent complex, formed by an oligonucleotide according to the second embodiment and a molecule comprising a first PI portion capable of binding to said at least one entity E of said oligonucleotide and a second P2 portion capable of binding to at least one analyte of interest.In other words, this non-covalent complex is formed by a linear oligonucleotide whose structure or portion Sa, Sb, Int, Sc, Sd, Sa', Sb', Int'', Sc' or Sd' and in particular the structure Sa, Sd, Sa' or Sd' comprises at least one entity E capable of indirectly binding to at least one analyte of interest as previously defined and a molecule comprising a first portion PI capable of binding to this at least one entity E present in the structure or portion Sa, Sb, Int, Sc, Sd, Sa', Sb', Int'', Sc' or Sd' and in particular the structure Sa, Sd, Sa' or Sd' and a second portion P2 capable of binding to at least one analyte of interest. Such a complex may be designated by the expression "binding complex".
[0069] The present invention also relates to the use of a linear oligonucleotide as previously defined or a binding complex as previously defined for detecting and optionally quantifying at least one analyte possibly present in a liquid sample.
[0070] This use more particularly implements a LAMP amplification with two primers, one, generally designated "FIP primer", of formula 5'-Flc-F2-3' and the other, generally designated "BIP primer", of formula 5'-Blc-B2-3'.
[0071] In a particular embodiment, the present invention relates to a method for detecting and optionally quantifying at least one analyte possibly present in a liquid sample, comprising the following steps: i) bringing said liquid sample into contact with the surface of a solid support comprising at least one active zone on which at least one probe capable of binding said at least one analyte is immobilized; ii) bringing said surface into contact with a solution containing either at least one linear oligonucleotide whose structure or portion Sa, Sb, Int, Sc, Sd, Sa', Sb', Int”, Sc' or Sd' comprises an entity E capable of binding directly to at least one analyte of interest as previously defined, or a binding complex as previously defined, said oligonucleotide and said complex having been prepared prior to said bringing into contact;iii) removing excess oligonucleotides or excess binding complexes not reacted during the contacting of step ii); iv) contacting, with two loop-mediated isothermal amplification primers under conditions allowing the amplification of said oligonucleotide, either said surface, or the linear oligonucleotide or the binding complex as previously defined, after having resuspended said oligonucleotide or said complex; v) detecting and optionally quantifying the product of the amplification of said oligonucleotide (whereby said at least one analyte is detected and optionally quantified).;
[0072] In another particular embodiment, the present invention relates to a method for detecting and optionally quantifying at least one analyte possibly present in a liquid sample, comprising the following steps: i') bringing said liquid sample into contact with the surface of a solid support comprising at least one active zone on which at least one probe capable of binding said at least one analyte is immobilized; iii') bringing said surface into contact with a solution containing at least one molecule comprising a first portion PI capable of binding to the entity E present in the structure of the oligonucleotide according to the present invention and a second portion P2 capable of binding to said at least one analyte of interest;
[0073] Ü2') eliminate the excess of molecules which have not reacted during the contacting of step iii');
[0074] Ü3') bringing said surface into contact with a solution containing at least one linear oligonucleotide whose structure or portion Sa, Sb, Int, Sc, Sd, Sa', Sb', Int”, Sc' or Sd' comprises an entity E capable of indirectly binding to said analyte of interest as previously defined, said oligonucleotide having been synthesized prior to said contacting; iii') removing the excess oligonucleotides which have not reacted during the contacting of step iis'); iv') bringing into contact, with two loop-mediated isothermal amplification primers under conditions allowing the amplification of said oligonucleotide, either said surface, or the linear oligonucleotide or the binding complex as previously defined, after having resuspended said oligonucleotide or said complex; v') detecting and optionally quantifying the product of the amplification of said oligonucleotide (whereby said at least an analyte is detected and possibly quantified).
[0075] The liquid sample used in the context of the present invention is a liquid likely to contain one or more analytes to be detected and possibly quantified. It can be of very varied nature and origin.
[0076] This liquid sample is advantageously chosen from the group consisting of a biological fluid; a plant fluid such as sap, nectar and root exudate; a sample from a culture medium or from a biological culture reactor such as a cell culture of higher eukaryotes, yeasts, fungi, algae or bacteria; a liquid obtained from one (or more) animal or plant cell(s); a liquid obtained from animal or plant tissue; a sample from a food matrix; a sample from a chemical reactor; city water, river water, sea water, swimming pool water, air-cooled tower water or water from underground sources; a sample from a liquid industrial effluent; wastewater originating in particular from intensive livestock farming or from industries in the chemical, pharmaceutical or cosmetic fields; a sample from air filtration or a coating;a sample taken from an object such as a piece of fabric, clothing, a sole, a shoe, a tool or a weapon; a pharmaceutical product; a cosmetic product; a perfume; a sample of soil or a mixture thereof. In the context of the present invention, "sampling" means any type of sample collection, for example, by contact, scraping, drilling, cutting, punching, grinding, washing, rinsing, suction or pumping.;
[0077] The biological fluid is advantageously selected from the group consisting of blood such as whole blood or anticoagulated whole blood, blood serum, blood plasma, lymph, saliva, sputum, tears, sweat, semen, urine, stool, milk, cerebrospinal fluid, interstitial fluid, fluid isolated from bone marrow, mucus or fluid from the respiratory, intestinal or genitourinary tract, cell extracts, tissue extracts and organ extracts. Thus, the biological fluid may be any fluid naturally secreted or excreted from a human or animal body or any fluid recovered from a human or animal body by any technique known to those skilled in the art such as extraction, sampling or washing. The steps of recovering and isolating these different fluids from the human or animal body are carried out prior to implementing the method according to the invention.
[0078] Likewise, if one of the samples envisaged does not allow the method of the invention to be implemented, for example due to its gaseous or solid nature, its concentration or the elements it contains such as solid residues, waste, suspension or interfering molecules, the method of the invention further comprises a preliminary step of preparing the liquid sample with possibly dissolving the sample using techniques known to those skilled in the art such as filtration, precipitation, dilution, distillation, mixing, concentration, lysis, etc.
[0079] Furthermore, it is possible to add known quantities of at least one analyte to be detected to the liquid sample. This is referred to as a liquid sample spiked with at least one analyte, this spike allowing for a positive control, particularly when the liquid sample is complex, and possibly for obtaining a quantification of the analyte(s) to be detected initially contained in the liquid sample.
[0080] An analyte to be detected and possibly quantified in the liquid sample may be chosen from the group consisting of a molecule of environmental interest such as a pesticide; a molecule of biological interest; a molecule of pharmacological interest; a toxin; a carbohydrate such as glucose; a lipid such as cholesterol; a peptide; an antigen; an epitope; a protein; a glycoprotein; an enzyme; an enzyme substrate; a nuclear or membrane receptor; an agonist or antagonist of a nuclear or membrane receptor; a hormone; a polyclonal or monoclonal antibody; an antibody fragment such as a Fab, F(ab')2, Fv fragment or a hypervariable domain (or CDR for "Complementarity Determining Region"); a nucleotide molecule as previously defined; ions such as mercury ions or lead ions; a eukaryotic cell; a prokaryotic cell and a virus.
[0081] Note that, in certain forms of implementation, an analyte to be detected and possibly quantified in the liquid sample can be defined as a small molecule, i.e. a molecule whose molecular weight is less than or equal to 10,000 daltons and in particular less than or equal to 8,000 daltons. This small molecule can belong to any of the elements of the lists of analytes above.
[0082] Step i) or i') of the method according to the present invention uses a probe capable of binding said at least one analyte immobilized on the surface of a solid support. The probe used to functionalize an active zone of the surface of the solid support is any molecule capable of forming a pair of bonds with an analyte to be detected, the probe and the analyte corresponding to the two partners of this pair of bonds. The bonds used in the analyte-probe bond are advantageously either non-covalent and low-energy bonds such as hydrogen bonds or Van der Waals bonds, or high-energy bonds of the covalent bond type.
[0083] The probe used is therefore dependent on an analyte to be detected. Depending on this analyte, the person skilled in the art will be able, without inventive effort, to choose the most suitable probe. It can be chosen, for example, from the group consisting of a carbohydrate; a peptide such as an antimicrobial peptide or a MIP ie a peptide associated with MHC-1 (for "Major Histocompatibility Complex-1"); an antigen; an epitope; a protein; a glycoprotein; an enzyme; an enzyme substrate; a membrane or nuclear receptor; an agonist or an antagonist of a membrane or nuclear receptor; a toxin; a polyclonal or monoclonal antibody; an antibody fragment such as a Fab, Ffab', Fv fragment or a hypervariable domain; a nucleotide molecule as previously defined; and an aptamer.
[0084] It is obvious that when choosing the most suitable probe, the recognition entity subsequently implemented should be taken into account. The probe and the recognition entity may recognize distinct areas or elements at the level of the analyte to be detected. Alternatively, the probe and the recognition entity may target the same element at the level of the analyte to be detected. This variant corresponds in particular to the case where the analyte to be detected is a bacterium or a virus and the element to be targeted is a surface element present at several bacterial or viral surface areas.
[0085] Any solid support that can be used to implement the present invention can be used. It may be, for example, a biochip support such as those conventionally used in silicon, glass, metal, polymer or plastic. This solid support may also consist of particles and in particular silica particles, polymeric particles and / or magnetizable particles.
[0086] The functionalization of the active zone of the surface of the solid support by a probe as previously defined can be carried out by any suitable technique allowing the attachment of a compound to a solid support. In particular, simple adsorption, ionic bonds, hydrogen bonds, electrostatic interactions, hydrophobic interactions, Van der Waals bonds or covalent grafting can be considered.
[0087] In a particular embodiment of the present invention, the surface of the solid support has functional groups by which the probe(s) are capable of being immobilized. Advantageously, these functional groups are chosen from carboxylic groups, radical entities, alcohol, amine, amide, epoxy or thiol functions. These groups are carried, intrinsically or by functionalization, by the active zone of the surface of the solid support. The probe(s) may also have such functional groups, intrinsically or by functionalization. In a first variant of the present invention, the probe(s) may be immobilized directly at the functionalized or non-functionalized surface. A solid support “coated” with a protein such as streptavidin is an example of direct immobilization, in which the probe must be functionalized with biotin.
[0088] In a second variant of the present invention, the probe(s) may be immobilized indirectly at the functionalized or non-functionalized surface. This indirect immobilization involves a spacer arm (or joining agent) linked, on the one hand, to the surface and, on the other hand, to a probe. Such a spacer arm is used in particular to improve accessibility to the probe. As illustrative examples, mention may be made of silane reagents used for grafting probes onto glass, complexing thiolated products onto gold surfaces and immobilizing probes in polymer matrices. In addition, when the probe(s) are one or more nucleotide molecules as previously defined, such a spacer arm may be in the form of a sequence comprising several thymine bases and in particular 10 thymine bases.
[0089] The bonds implemented during direct or indirect immobilization may be any bonds known to those skilled in the art and in particular covalent bonds, ionic bonds, hydrogen bonds, electrostatic interactions, hydrophobic interactions, Van der Waals bonds or adsorption.
[0090] Advantageously, a surface blocking step may be implemented prior to the attachment of the probe and / or following this attachment. The blocking solution implemented during this blocking step may comprise one or more of the following components: albumin such as BSA (for “Bovine Serum Albumin”), genomic DNA such as single-stranded DNA and in particular single-stranded DNA from salmon sperm, gelatin, casein, milk proteins, serum, polyethylene glycol and polymers of the polyvinylpyrrolidone type. A particular example of a blocking solution is a solution containing from 1% to 5% of BSA and optionally 20 pg / mL of single-stranded DNA from salmon sperm.Step i) or i') of the method according to the invention consists in bringing the liquid sample as previously defined into contact with the surface of a solid support functionalized by one or more probes capable of binding the analyte to be detected, whereby, if the liquid sample contains this analyte, the latter is captured at the level of the probe(s).
[0091] Typically, the contacting step i) or i') may last between 1 min and 24 h, between 2 min and 12 h, between 5 min and 6 h, between 10 min and 3 h, between 15 min and 2 h, between 20 min and 1 h and, in particular, of the order of 30 min (i.e. 30 min ± 5 min). Furthermore, the contacting step i) may be carried out at a temperature of between 4°C and 70°C, in particular between 10°C and 60°C, in particular between 15 and 45°C and, more particularly, at room temperature (i.e. 23°C ± 5°C) or at physiological temperature (i.e. 37°C ± 5°C).
[0092] Following step i) or i') and prior to step ii) or iii') of the method according to the present invention, it is possible to eliminate the elements present in the liquid sample and which have not been captured by the probe(s). Any technique allowing such elimination can be used within the scope of the present invention. By way of example, mention may be made of washing the surface of the solid support or the separation of the liquid sample and the solid support such as a physical or magnetic separation. However, this elimination step is optional since these elements may be eliminated subsequently and in particular during any one of steps iii), 2') or iii').
[0093] When this removal step is implemented, the surface of the solid support may be subjected to at least one rinse to remove all traces of the liquid sample. This rinse is typically carried out with an aqueous rinsing solution that preserves the probe / analyte interaction or irreversibly binds the analyte and the probe. This solution may also eliminate nonspecific interactions. It may include one or more of the following components: a buffer such as a Tris, phosphate, acetate or borate buffer; salts such as KCl, NaCl, (NF hSC ), MgC or CaC; detergents or surfactants such as Tween®, Triton® or sodium dodecyl sulfate (or SDS); denaturing agents such as formamide or dimethyl sulfoxide; an organic solvent such as ethanol, methanol or acetonitrile; and bridging agents such as formaldehyde or glutaraldehyde.This rinse can be repeated two, three, five, 10, or even 50 times using the same or different rinse solution for each rinse. Typically, the rinse is repeated three times with a solution comprising (i) phosphate buffered saline (or PBS) and 0.1% Tween® such as Tween®20, (ii) PBS, 0.3% Tween® such as Tween®20, and 1 M NaCl, or (iii) a saline solution containing 0.02 M PBS, 1.074 M NaCl, and 0.3% Tween® such as Tween®20.
[0094] Furthermore, when this optional elimination step is implemented, it is carried out at a temperature between 4°C and 100°C, in particular between 10°C and 60°C, in particular between 15°C and 45°C and, more particularly, at room temperature or at physiological temperature.
[0095] Step ii) of the method according to the present invention consists in bringing into contact the surface of the solid support on which an analyte to be detected is optionally retained via the probe(s) functionalizing this surface with a solution containing at least one linear oligonucleotide, capable of binding to said analyte or at least one binding complex as previously defined, whereby, if this analyte is present on the surface of the solid support, the oligonucleotide or the binding complex binds to the latter respectively via its recognition entity or its P2 portion. In other words, the linear oligonucleotide or the binding complex is capable of forming a binding pair with the analyte to be detected, the oligonucleotide or the binding complex and the analyte corresponding to the two partners of this binding pair.The bonds implemented in the oligonucleotide-analyte bond or in the complex-analyte bond are advantageously non-covalent and low-energy bonds such as hydrogen bonds or Van der Waals bonds and / or high-energy bonds of the covalent bond type.
[0096] The oligonucleotide according to the invention was synthesized prior to the contact in step ii) or iis'). In other words, this synthesis is carried out neither in the presence of the surface of the solid support functionalized by the probe(s) as previously defined, nor in the presence of the analyte to be detected. Advantageously, this synthesis is a chemical synthesis conventionally used to prepare oligonucleotides.
[0097] In step ii) of the method according to the present invention, the surface of the solid support on which at least one analyte is optionally held by means of a probe is brought into contact with a solution containing at least one linear oligonucleotide as previously defined or a binding complex as previously defined. This solution is advantageously an aqueous solution allowing the dumbbell or complex / analyte interaction. It may comprise one or more of the following components: a buffer such as a Tris, phosphate, acetate or borate buffer; salts such as KCl, NaCl, (NF hSC ), MgC or CaC; detergents or surfactants such as Tween®, Triton® or sodium dodecyl sulfate (or SDS); denaturing agents such as formamide or dimethyl sulfoxide; an organic solvent such as ethanol, methanol or acetonitrile; and bridging agents such as formaldehyde or glutaraldehyde.Advantageously, when the oligonucleotide comprises an aptamer sequence for the recognition of the analyte, the solution used will be composed of the elements in whole or in part constituting the selection buffer of the aptamer. The solution used during step ii) may, in addition, comprise one or more elements chosen from genomic DNA such as single-stranded DNA and in particular single-stranded DNA from salmon sperm, serum, albumin, a synthetic polymer, a blocking agent such as the Denhardt blocking agent and any other element making it possible to limit non-specific adsorption. A particular example of a solution used during step ii) is a saline solution containing 0.02 M PBS, 1.074 M NaCl, 0.3% Tween20 detergent, 20 pg / mL salmon sperm DNA and 4% Denhardt blocking agent.
[0098] Furthermore, the linear oligonucleotide or the binding complex is present in this solution in an amount of between 1 aM and 1 mM, and in particular between 100 aM and 1 pM. As particular examples of concentrations that can be used, mention may be made of a concentration of 10 pM, 100 pM, 1 nM, or 10 nM. Advantageously, the linear oligonucleotide or the binding complex is present in the solution used during step ii) at a concentration of 100 pM. Typically, step ii) of contacting can last between 1 min and 24 h, in particular between 2 min and 12 h and, in particular, between 5 min and 6 h. In a particular form of implementation, this contacting can last between 10 min and 3 h, between 15 min and 2 h, between 20 min and 1 h and, in particular, of the order of 30 min (i.e. 30 min ± 5 min). In another form of implementation, this implementation can last between 30 min and 6 h, between 1 h and 5 h, between 2 h and 4 h and, in particular, of the order of 3 h (i.e.3 h ± 15 min). Similarly, step (ii) of contacting can be carried out at a temperature between 4°C and 100°C, in particular between 10°C and 60°C, in particular between 15 and 30°C and, more particularly, at room temperature (i.e. 23°C ± 5°C) or at physiological temperature (i.e. 37°C ± 5°C).
[0099] Prior to this contact, it is possible to heat the oligonucleotide according to the invention to a temperature above 80°C and in particular of the order of 90°C (i.e. 90°C ± 5°C) for 5 min and then to cool it to room temperature in approximately 35 min (35 min ± 10 min). This preliminary step makes it possible, in particular when the recognition entity is an aptamer, to give the latter an optimal conformation for the detection of the analyte.
[0100] Everything described above for step ii) (nature of the solution, duration and temperature) applies to steps iii') and iis'). In addition, the molecule comprising a first portion P1 and a second portion P2 as previously defined and the linear oligonucleotide is present in the solution during contacting respectively in step iii') and in step iis') in an amount of between 1 aM and 1 mM, and in particular between 100 aM and 1 pM. As particular examples of concentrations that can be used, mention may be made of a concentration of 10 pM, 100 pM, 1 nM, or 10 nM.
[0101] Following step ii) or iis') and prior to LAMP amplification or following step iii') and prior to step iis'), it is necessary to eliminate all elements likely to give false positives, such as, for example, linear oligonucleotides or molecules with PI and P2 portions or binding complexes not specifically bound to the analyte to be detected or bound to elements not bound to the probes functionalizing the surface of the solid support. This is step iiz'), iii) or iii') of the method according to the present invention.
[0102] Any technique allowing such removal can be used within the scope of the present invention. For example, mention may be made of washing the surface of the solid support or separating the solution containing linear oligonucleotides or molecules with PI and P2 portions or binding complexes from the solid support such as physical or magnetic separation.
[0103] When this removal step is implemented, the surface of the solid support may be subjected to at least one rinsing which is typically carried out with a rinsing solution consisting of an aqueous solution: preserving the analyte / oligonucleotide interaction or irreversibly binding the analyte and the oligonucleotide (case of step iii));
[0104] - retaining the analyte / binding complex interaction or irreversibly binding the analyte and the binding complex (case of step iii) and step iii')) or
[0105] - preserving the analyte / molecule interaction with PI and P2 portions or irreversibly binding the analyte and the molecule with PI and P2 portions (case of the Hz' step))-
[0106] This rinsing solution can also eliminate non-specific interactions. It can include one or more of the following components: a buffer such as Tris, phosphate, acetate or borate buffer; salts such as KCl, NaCl, (NFUhSC , MgC or CaC; detergents or surfactants such as Tween®, Triton® or sodium dodecyl sulfate (or SDS); denaturing agents such as formamide or dimethyl sulfoxide; an organic solvent such as ethanol, methanol or acetonitrile; and bridging agents such as formaldehyde or glutaraldehyde and one or more elements selected from genomic DNA such as single-stranded DNA and in particular single-stranded salmon sperm DNA, serum, albumin and a synthetic polymer. This rinsing can be repeated two, three, five, 10 or even 50 times using, for each rinse, an identical or different rinsing solution.Typically, the rinse is repeated three times with a solution comprising PBS and 0.1% Tween®. Alternatively, the rinse is repeated three times with a saline solution containing 0.02 M PBS, 1.074 M NaCl, and 0.3% Tween®20 detergent.
[0107] In addition, step Hz'), iü) or iii') is carried out at a temperature between 4°C and 100°C, in particular between 15°C and 80°C, in particular between 30°C and 60°C and, more particularly, at a temperature of the order of 40°C (i.e. 40°C ± 5°C) or at physiological temperature.
[0108] Step iv) or iv') of the method according to the invention is the two-primer LAMP amplification itself. The only two primers used are the FIP and BIP primers as previously defined, namely the primers with the respective sequences 5'-Flc-F2-3' and 5'-Blc-B2-3'.
[0109] The melting temperature (Tm) of B2-B2c is in particular higher than the temperature used during the amplification. The Tm of B2-B2c is higher than the temperature used during the amplification advantageously by at least 5°C, in particular by at least 7°C and, in particular, by at least 10°C. Those skilled in the art will be able to find additional information regarding these portions in [1],
[0110] The melting temperature (Tm) of F2-F2c is in particular higher than the temperature used during the amplification. The Tm of B2-B2c is higher than the temperature used during the amplification advantageously by at least 5°C, in particular by at least 7°C and, in particular, by at least 10°C. Those skilled in the art will be able to find additional information regarding these portions in [1],
[0111] It should be noted that in step iv) or iv') of the method according to the present invention, the analyte is not used as a primer for LAMP amplification.
[0112] In one embodiment, step iv) or iv') of the method according to the present invention consists in bringing into contact the surface on which one or more probes specific to the analyte(s) to be detected are immobilized with a reaction mixture comprising the FIP and BIP primers and any element necessary for the production of an amplification product if the linear oligonucleotide is present.
[0113] In another particular embodiment, it is possible to implement step iv) or iv') after having resuspended the linear oligonucleotide or the binding complex as previously defined. In this embodiment, it is appropriate to subject the solid support to which the linear oligonucleotide is indirectly bound via the analyte of interest and possibly a molecule with P1 and P2 portions, to a treatment such as a thermal or chemical treatment, so as to separate the binding partners which are (i) the linear oligonucleotide and the analyte of interest, (ii) the linear oligonucleotide and the molecule with P1 and P2 portions, and / or (iii) the molecule with P1 and P2 portions and the analyte of interest. Without inventive effort, a person skilled in the art will be able to determine the most suitable treatment depending on the binding partners used.This particular embodiment allows, once the oligonucleotide or the binding complex is resuspended, to eliminate the surface on which the analyte has been fixed before carrying out the LAMP with the supernatant alone.
[0114] Typically, the reaction mixture used in step iv) or iv') comprises a suitable buffer, such as, for example, a phosphate buffer or a Tris buffer; deoxyribonucleosides (dNTPs), such as an equimolar mixture of dATP, dCTP, dGTP and dTTP and an enzyme catalyzing LAMP amplification. Such an enzyme is a polymerase exhibiting high strand displacement activity in addition to replication activity. As particular examples of such enzymes, one of the enzymes listed below may be used:
[0115] - Bst DNA polymerase and its variants such as, for example, Bst2.0 DNA polymerase and Bst3.0 DNA polymerase,
[0116] - Bsm DNA polymerase,
[0117] - Bca (exo-) DNA polymerase,
[0118] - Klenow fragment of DNA polymerase I,
[0119] - Vent DNA polymerase,
[0120] - Vent(Exo-) DNA polymerase (exonuclease activity-free Vent DNA polymerase),
[0121] - DeepVent DNA polymerase,
[0122] - DeepVent(Exo-) DNA polymerase (DeepVent DNA polymerase sans activité exonucléase),
[0123] - 29 phage DNA polymerase, - MS-2 phage DNA polymerase,
[0124] - Z-Taq DNA polymerase (Takara Shuzo), et
[0125] - KOD DNA polymerase (TOYOBO).
[0126] The reaction medium may further comprise salts such as magnesium salts, manganese salts and / or ammonium salts; detergents, betaine and / or elements useful for the detection and quantification of the amplification product of the linear oligonucleotide such as, for example, calcein, an intercalating dye such as, for example, propidium iodide, SYTO 9, SYBR green and EvaGreen.
[0127] Step iv) or iv') of the method according to the present invention is carried out for a period of time and at a temperature sufficient for the production of an amplification product if the linear oligonucleotide is present. Advantageously, this step is carried out under isothermal conditions and in particular at a temperature of between 15°C and 90°C, in particular, of between 50°C and 80°C and, more particularly, of the order of 65°C (i.e. 65°C ± 5°C). The duration of step iv) or iv') of the method according to the present invention is between 1 min and 120 min, in particular between 5 min and 90 min and, in particular, between 10 min and 60 min.
[0128] Step v) or v') consists of detecting and possibly quantifying the amplification product of the linear oligonucleotide and therefore detecting and possibly quantifying the analyte to which the linear oligonucleotide is or has been bound since the accumulation of the amplification product is an indicator of the presence of this analyte immobilized on the surface of the solid support.
[0129] Step v) or v') may be carried out simultaneously with step iv) or iv') or after the latter. Those skilled in the art know different techniques for carrying out this detection. The latter may in particular be any of the techniques described in Becherer et al, 2020 [7],
[0130] The amplification product can be detected, in step v) or v') by measuring the turbidity caused by the magnesium pyrophosphate precipitated in solution as a by-product of the amplification. This measurement can be carried out by the naked eye or via a turbidimeter or by lensless imaging [8].
[0131] The amplification product can be detected, during step v) or v'), by a pH probe making it possible to monitor the acidification of the reaction mixture during LAMP amplification.
[0132] The amplification product can be detected, during step v) or v'), via gel electrophoresis.
[0133] The amplification product can be detected, in step v) or v'), by in-plane crystal detection by lensless imaging as described in [8].
[0134] The amplification product can also be detected, during step v) or v'), by a colorimetric test or by fluorescence measurement, in particular when calcein or a fluorescent intercalating dye is present in the reaction mixture.
[0135] When it is desired to carry out a quantification of at least one analyte during step v) or v') of the method according to the present invention, this quantification is carried out by a comparison with a standard range of analyte at known concentrations. This quantification is a classic step of the ELISA method. This quantification can also implement known quantities of analyte to be detected, added to the liquid sample as previously envisaged (spiked liquid sample).
[0136] Other characteristics and advantages of the present invention will become apparent to those skilled in the art upon reading the examples below given for illustrative and non-limiting purposes, with reference to the appended figures.
[0137] BRIEF DESCRIPTION OF THE DRAWINGS
[0138] Figure 1 shows the LAMP calibration range of linear oligonucleotides according to the invention (M1 and M2) and compared to that of a minimal dumbbell (M3). Figure 2 shows the principle of direct detection of a single strand of DNA complementary to the recognition entity of a linear oligonucleotide according to the invention, M2.
[0139] Figure 3 shows the amplification curves of a linear oligonucleotide according to the invention, M2, during its hybridization on the complementary DNA strand immobilized on the magnetic beads (experimental duplicates).
[0140] Figure 4 shows the calibration range of a linear oligonucleotide, M2, during its hybridization on the complementary DNA strand immobilized on magnetic beads (N=4).
[0141] Figure 5 shows the principle of detection of a protein (antibody 1) fixed on magnetic beads by immunoLAMP: grafting of antibodies onto the linear oligonucleotide according to the invention using a PI portion, here “Zip6c” which recognizes the “Zip6” recognition entity of the oligonucleotide, the antibody corresponding to the P2 portion (left), by covalent bond (center) and by biotin-streptavidin bond (right).
[0142] Figure 6 shows the setup of immunoLAMP protocols including an antibody functionalized with the linear oligonucleotide according to the invention and various negative controls.
[0143] Figure 7 shows the amplification curve (fluorescence versus time) of the detection of proteins immobilized on beads by an antibody functionalized with a “Zip6c” oligonucleotide strand then linked to the oligonucleotide according to the invention by 2-primer LAMP. The legend corresponds to the diagrams in Figure 6.
[0144] DETAILED DESCRIPTION OF SPECIFIC EMBODIMENTS
[0145] I. Amplification of the oligonucleotide according to the invention by two-primer LAMP.
[0146] To prove the functionality of the two-primer LAMP, several sequences are used: - a linear oligonucleotide according to the invention designated Ml with a 40-base recognition entity E1 consisting of an anti-thrombin aptamer called “Thrl” [9],
[0147] - a linear oligonucleotide according to the invention designated M2 with a
[0148] 5 E2 recognition entity of 24 bases consisting of an oligonucleotide sequence “Zip6”, and
[0149] - a dumbbell with a double rod-loop structure as presented in [5, 6] and used here as a reference. This dumbbell is called “minimal” because it does not contain any recognition entities. 0
[0150] The sequences of the two oligonucleotides M1 and M2, of the minimal dumbbell M3 and of the primers FIP and BIP used during LAMP amplification are given in Table 1 below.
[0151] Table 1
[0152] Several solutions of oligonucleotides M1 and M2 and dumbbell M3 at different concentrations were amplified using the two-primer LAMP amplification protocol.
[0153] This protocol consists of adding 2 pL of oligonucleotide or dumbbell solution diluted in a buffer containing PBS and MgC (pH = 7.3) with 18 pL of reaction mix comprising:
[0154] - an enzyme catalyzing the amplification, Bst DNA Polymerase for example, with its associated amplification buffer, such as “isothermal amplification buffer (NEB)” for example,
[0155] - deoxyribonucleoside triphosphates (d NTPs),
[0156] - magnesium salts such as MgC,
[0157] - an intercalating dye such as EvaGreen,
[0158] - betaine and
[0159] - FIP and BIP primers as defined below.
[0160] The calibration range comparing the 3 sequences is presented in Figure 1. This represents the threshold cycle values known as “Ct” as a function of the logarithm of the DNA template concentration. The Ct value is defined by the time from which the fluorescence value is greater than a threshold fluorescence value.
[0161] Figure 1 validates the two-primer LAMP amplification of oligonucleotides M1 and M2. Their amplification is slower than the double-loop “dumbbell” version i.e. M3, but they have the advantage of having a much shorter strand length, allowing easy synthesis.
[0162] These oligonucleotides are then subsequently used in various configurations including a recognition entity for detection applications. II. Use of an oligonucleotide according to the present invention in detection.
[0163] The oligonucleotide M2 is used in detection, because it includes a recognition entity part "Zip6" allowing hybridization on the complementary sequence "Zip6c". The sequence of "Zip6" and that of "Zip6c" are respectively 5'-GACCGGTATGCGACCTGGTATGCG-3' (SEQ ID NO: 6 in the attached sequence listing) and 5'-CGCATACCAGGTCGCATACCGGTC-3' (SEQ ID NO: 7 in the attached sequence listing).
[0164] Compared to the dumbbells used in detection in [5, 6], the M2 oligonucleotide has the advantage of being short and generic because it can hybridize to any type of probe.
[0165] 11.1. Quantification range of oligonucleotides on beads (direct).
[0166] The detection of DNA strands immobilized on magnetic beads was carried out and made it possible to show that the oligonucleotide according to the invention makes it possible to detect a single strand of DNA when it is complementary to the sequence placed at the 5' end.
[0167] A range of different concentrations of oligonucleotide M2 mixed with beads on which the DNA strand complementary to the recognition entity "Zip6" is grafted via a 10 thymine base linker "10T-Zip6c", is produced. The solution containing the beads and the matrix is amplified, after carrying out 3 washes to eliminate the oligonucleotides that have not attached to the target. The principle of the detection protocol is shown in Figure 2.
[0168] The detection protocol is then as follows:
[0169] - incubation of the biotinylated DNA strand “10T-Zip6c” with the streptavidin magnetic beads at 25°C for 10 min then 3 rinses using a magnet and a rinsing buffer
[0170] - blocking of magnetic beads for 30 min using a 1% BSA solution - incubation of different concentrations of oligonucleotide M2 (1 nM -
[0171] 100 pM) at 37°C for 30 min, then 3 rinses with the rinsing buffer,
[0172] - addition of the LAMP solution containing the 2 primers and the enzyme necessary for amplification
[0173] This protocol allows to obtain a range of amplification of the oligonucleotide when its 5' end hybridizes with the complementary strand placed on the beads. The amplification curves obtained and the associated calibration range are shown in Figure 3 and Figure 4.
[0174] 11.2. Protein detection: ImmunoLAMP.
[0175] Another example of using a linear oligonucleotide according to the invention is to use it with antibodies. This makes it possible to combine the specificity of antibody recognition with the sensitivity provided by the LAMP amplification of this oligonucleotide, in order to detect molecules present in very small quantities in fluids. This technique is equivalent to the immunoPCR techniques known and used for around twenty years, but uses LAMP amplification which has the advantage of being isothermal [2],
[0176] Thanks to the present invention, this protocol is further simplified because the linear oligonucleotide used for LAMP is shortened and uses only 2 primers. For this, an antibody can be grafted to the oligonucleotide by biotin-streptavidin bond, by covalent bond at the 5' end or via a PI portion, here "Zip6c" which recognizes the recognition entity "Zip6" of the oligonucleotide, the antibody corresponding to the P2 portion, as shown in Figure 5. This type of configuration makes it possible to make a sandwich with two antibodies followed by LAMP amplification, combining specificity and sensitivity of recognition.
[0177] This protein detection was set up as an example with an anti-mouse antibody 1 and an anti-CD63 antibody 2 produced in mice. Firstly, the antibody 2 is functionalized with an oligonucleotide strand "Zip6c", complementary to the "Zip6" part present in the linear oligonucleotide according to the invention). A covalent bond is then established between the antibody 2 and the oligonucleotide strand thanks to a reaction between a thiol molecule attached to the oligonucleotide and the SM(PEG)i2 molecule attached to the antibody 2. This complex is then brought into contact with the oligonucleotide according to the invention, amplifiable by 2-primer LAMP, which binds to it by DNA hybridization, forming a protein recognition complex and amplifiable by 2-primer LAMP.
[0178] The detection protocol is then as follows:
[0179] - incubation of biotinylated antibody 1 specific for antibody 2 on the magnetic beads for 30 min with shaking at 25°C, then 3 rinses using a magnet and a solution of PBS, 1% BSA and 0.3% Tween 20,
[0180] - blocking of the magnetic beads for 30 min using a 1% BSA solution,
[0181] - incubation of antibody 2 specific for antibody 1 and functionalized with the oligonucleotide according to the invention, for 30 min, with stirring at 25°C, then 3 rinses using a magnet and a solution of PBS, 1% BSA and 0.3% Tween 20,
[0182] - addition of the LAMP solution containing the 2 primers and the enzyme necessary for amplification
[0183] In parallel with this detection protocol, negative controls (Figure 6) are carried out with antibodies 1 not specific to antibody 2, as follows:
[0184] - Negative control 1: Antibody 1 specific for antibody 2 and addition of the oligonucleotide according to the invention, not functionalized with the antibody,
[0185] - Negative control 2: Ibis antibody not specific to antibody 2,
[0186] - Negative control 3: No antibody 1 added.
[0187] This protocol allows to observe the protein detection by this ImmunoLAMP method. The results obtained are presented in Figure 7.
[0188] The latter demonstrates the specificity of protein recognition followed by LAMP amplification. Indeed, the fluorescence signal corresponding to the detection appears earlier (a few minutes) compared to the negative controls. The results presented here highlight the possibility of implementing 2-primer ImmunoLAMP detection protocols with the linear oligonucleotide according to the invention.
[0189] Bibliographic references
[0190] [1] US Patent 6,410,278 published June 25, 2002.
[0191] [2] Pourhassan-Moghaddam et al, 2013, “Protein detection through different platforms of immuno-loop-mediated isothermal amplification”, Nanoscale Research Letters, vol. 8:485, pages 1-11.
[0192] [3] Du et al, 2016, “A ligation-based loop-mediated isothermal amplification (ligation-LAMP) strategy for highly selective microRNA detection”, Chem. Commun., vol. 52, pages 12721-12724.
[0193] [4] Patent application CN 106148549 published on November 23, 2016.
[0194] [5] Patent application EP 3878971 published on September 15, 2021.
[0195] [6] Patent application FR 2109667 filed on September 15, 2021.
[0196] [7] Becherer et al, 2020, “Loop-mediated isothermal amplification (LAMP) - review and classification of methods for sequence-specific detection”, vol. 12, pages 717-746.
[0197] [8] Patent application EP 3363913 published on August 22, 2018.
[0198] [9] Daniel et al, 2013, “Real-time monitoring of thrombin interactions with its aptamers: Insights into the sandwich complex formation”, Biosens. Bioelectron., vol. 40, pages 186-192.
Claims
37 DEMANDS 1) Use of a linear oligonucleotide corresponding to the following formula (I): Sa-F2-Sb-Fl-lnt-Blc-Sc-B2c-Sd (I) in which Sa represents the 5' end of portion F2 or a structure comprising at least one entity E capable of binding, directly or indirectly, to an analyte of interest; portion F2 comprises 8 to 30 nucleotides, Sb separating portion F2 and portion Fl is either a covalent bond, or a portion comprising at least one entity E capable of binding, directly or indirectly, to an analyte of interest; portion Fl comprises 10 to 35 nucleotides. The int separating the Fl portion and the Blc portion is chosen from the group formed by a covalent bond, a portion comprising at least one nucleotide and a portion comprising at least one entity E capable of binding, directly or indirectly, to an analyte of interest; the Blc portion comprises 10 to 35 nucleotides. The Sc separating the Blc portion and the B2c portion is either a covalent bond or a portion comprising at least one E entity capable of binding, directly or indirectly, to an analyte of interest; the B2c portion comprises 8 to 35 nucleotides, and Sd represents the 3' end of portion B2c or a structure comprising at least one entity E capable of binding, directly or indirectly, to an analyte of interest, provided that at least one of Sa, Sb, Int, Sc and Sd comprises a structure or portion comprising at least one entity E capable of binding, directly or indirectly, to an analyte of interest, 38 to detect and possibly quantify at least one analyte possibly present in a liquid sample, said detection and possible quantification employing isothermal amplification mediated by two-primer loops, one of formula 5'-Flc-F2-3' and the other of formula 5'-Blc-B2-3'. 2) Use according to claim 1, characterized in that said oligonucleotide corresponds to any one of the following formulas (II), (III), (IV), (V) and (VI): Sa'-F2-Fl-lnt'-Blc-B2c (II) F2-Sb'-Fl-lnt'-Blc-B2c (III) F2-Fl-lnt"-Blc-B2c (IV) F2-Fl-lnt'-Blc-Sc'-B2c (V) and F2-Fl-lnt'-Blc-B2c-Sd' (VI) wherein the portions F2, Fl, Blc and B2c are as defined in claim 1, The interval separating the Fl portion and the Blc portion is either a covalent bond or a portion comprising at least one nucleotide, and Sa', Sb', Int'', Sc' and Sd' represent a structure or portion comprising at least one entity E capable of binding, directly or indirectly, to an analyte of interest. 3) Use according to claim 1 or 2, characterized in that - said portion F2 comprises from 10 to 27 nucleotides, - said portion Fl comprises 15 to 25 nucleotides, - said Blc portion comprises 17 to 27 nucleotides, and / or - said portion B2c comprises 15 to 30 nucleotides. 4) Use according to any one of claims 1 to 3, characterized in that said structure or portion Sa, Sb, Int, Sc, Sd, Sa', Sb', Int'', Sc' or Sd' comprises, in addition to an entity, at least one other element enabling the entity E to be linked to the 5' end of portion F2, to the 3' end of portion F2, to the 3' end of portion Fl, to the 5' end of portion Fl, to the 5' end of portion Blc, to the 3' end of portion Blc, to the 5' end of portion B2c and / or to the 3' end of portion B2c. 5) Use according to any one of claims 1 to 4, characterized in that said at least one entity E present at the level of said structure or portion Sa, Sb, Int, Sc, Sd, Sa', Sb', Int'', Sc' or Sd' is capable of binding directly to at least one analyte of interest. 6) Use according to claim 5, characterized in that said at least one entity E is selected from the group consisting of a carbohydrate; a peptide such as an antimicrobial peptide or an MIP, i.e. a peptide associated with MHC-1 (for "Major Histocompatibility Complex-1"); an antigen; an epitope; a protein; a glycoprotein; an enzyme; an enzyme substrate; a membrane or nuclear receptor; an agonist or antagonist of a membrane or nuclear receptor; a toxin; a polyclonal or monoclonal antibody; an antibody fragment such as a Fab, F(ab')2, Fv fragment or a hypervariable domain (or CDR for "Complementarity Determining Region"); a nucleotide molecule; and an aptamer. 7) Use according to any one of claims 1 to 4, characterized in that said at least one entity E present at the level of said structure or portion Sa, Sb, Int, Sc, Sd, Sa', Sb', Int'', Sc' or Sd' is capable of binding indirectly to at least one analyte of interest. 8) Use of a non-covalent complex, formed by a linear oligonucleotide as defined in claim 7 and a molecule comprising a first portion Pl capable of binding to said at least one entity E of said oligonucleotide and a second portion P2 capable of binding to at least one analyte of interest, to detect and possibly quantify at least one analyte possibly present in a liquid sample, said detection and possible quantification employing isothermal amplification mediated by two-primer loops, one of formula 5'-Flc-F2-3' and the other of formula 5'-Blc-B2-3'. 9) A method for detecting and possibly quantifying at least one analyte possibly present in a liquid sample, comprising the following steps: i) bringing said liquid sample into contact with the surface of a solid support comprising at least one active area on which at least one probe capable of binding said at least one analyte is immobilized; ii) bringing said surface into contact with a solution containing either at least one linear oligonucleotide as defined in claim 5 or 6, or a complex as defined in claim 8, said oligonucleotide and said complex having been prepared prior to said contacting; iii) removing the excess oligonucleotides or the excess binding complexes that did not react during the contacting in step ii);(iv) to bring into contact, with two loop-mediated isothermal amplification primers, one of formula 5'-Flc-F2-3' and the other of formula 5'-Blc-B2-3', under conditions permitting the amplification of said oligonucleotide, either said surface, or the linear oligonucleotide as defined in claim 5 or 6 or the linking complex according to claim 8, after having resuspended said oligonucleotide or said complex; (v) to detect and possibly quantify the product of the amplification of said oligonucleotide. 10) A method for detecting and possibly quantifying at least one analyte possibly present in a liquid sample, comprising the following steps: i') bringing said liquid sample into contact with the surface of a solid support comprising at least one active area on which at least one probe capable of binding said at least one analyte is immobilized; iii') bringing said surface into contact with a solution containing at least one molecule comprising a first portion PI capable of binding to the entity E present in the structure of the oligonucleotide according to claim 7 and a second portion P2 capable of binding to said at least one analyte of interest; Ü2') eliminate the excess of molecules that did not react during the contact in step iii'); 3') bring said surface into contact with a solution containing at least one linear oligonucleotide according to claim 7, said oligonucleotide having been synthesized prior to said contact; iii') remove the excess oligonucleotides that did not react during the contact in step iis'); iv') bring into contact with two loop-mediated isothermal amplification primers, one of formula 5'-Flc-F2-3' and the other of formula 5'-Blc-B2-3', under conditions allowing the amplification of said oligonucleotide, either said surface, or the linear oligonucleotide according to claim 7 or the linker complex according to claim 8, after having resuspended said oligonucleotide or said complex; v') detect and optionally quantify the product of the amplification of said oligonucleotide. 11) Method according to claim 9 or 10, characterized in that said amplification product is detected, during said step v) or v'), by turbidity measurement, by lensless imaging, by a pH probe, via gel electrophoresis, by a colorimetric test or by fluorescence measurement.
